Technology & Innovation

Impact of ISO 15197:2013 on Product Discontinuation

The introduction of ISO 15197:2013 marked a pivotal regulatory shift in the diabetic test strip market, tightening accuracy requirements from ±20% to ±15% and mandating stricter interference testing. This standard acted as a filter that forced the discontinuation of inferior technologies.

Key Impacts:

  • Obsolescence of Photometry: Older light-based sensors generally could not meet the new precision standards and were phased out in favor of electrochemical sensors.
  • Chemistry Shift: The requirement to test for interferences accelerated the removal of GDH-PQQ enzymes (susceptible to maltose interference) in favor of highly specific GDH-FAD and Mut. Q-GDH chemistries.
  • Market Consolidation: The high R&D and manufacturing costs required to achieve ±15% accuracy (e.g., implementing hematocrit correction algorithms and laser ablation) forced many low-cost "white-label" generic manufacturers out of regulated markets like the EU and US.
  • Regulatory Alignment: The adoption of these standards by the EU (2016 deadline) and the FDA (2016 Guidance) compelled major manufacturers to sunset legacy product lines and migrate users to modern, high-accuracy platforms.
1 min read
Advanced
6 glossary terms
3 citations

Introduction of ISO 15197:2013

The ISO 15197:2013 standard revolutionizes the diabetic test strip market. It tightens accuracy requirements to ±15% and enforces stricter interference testing. This standard forces inferior technologies out.

Key Impacts

  • Photometry Obsolescence: Electrochemical sensors replace older light-based sensors due to their inability to meet new precision standards.
  • Chemistry Shift: Manufacturers replace GDH-PQQ enzymes with GDH-FAD and Mut. Q-GDH chemistries to address maltose interference.
  • Market Consolidation: High R&D and manufacturing costs force low-cost generic manufacturers out of regulated markets.
  • Regulatory Alignment: The EU and FDA adopt these standards, leading to the discontinuation of legacy product lines and migration to modern platforms.

References

  1. Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use: Guidance for Industry and Food and Drug Administration StaffSource
  2. System Accuracy Evaluation of 43 Blood Glucose Monitoring Systems for Self-Monitoring of Blood Glucose according to DIN EN ISO 15197Source
  3. Lot-to-Lot Variability of Blood Glucose Monitoring SystemsSource

Was this article helpful?

Explore More Topics

Continue your research with related categories